LIFE HEALTHCARE GROUP HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
(Registration number: 2003/002733/06)
Income tax number: 9387/307/15/1
ISIN: ZAE000145892
JSE and A2X share Code: LHC
("Life Healthcare" or "the Group" or "the Company")

LIFE HEALTHCARE FUNDING LIMITED
(Incorporated in the Republic of South Africa with limited liability)
(Registration number 2016/273566/06)
LEI: 3789SJPQJZF8ZYXTZ394
Bond company code: LHFI
("Life Healthcare Funding")

SUMMARISED GROUP RESULTS FOR THE YEAR ENDED 30 SEPTEMBER 2026 AND CASH DIVIDEND DECLARATION

- Revenue growth of 1.7% to R25.5 billion
- Normalised EBITDA up 6.7% with margin expansion of 80bps
- Solid underlying operational performance (7.4% increase in operating profit before non-trading items)
- Normalised earnings per share (NEPS) increased by 9.5% to 109.8 cents per share
- Healthy gearing of 1.06 times and a return on capital employed (ROCE) of 17.7%
- The Board has declared a final cash dividend of 40.0 cents per share, an increase of 14.3% compared to the prior year
- Share buyback commenced in August 2026. 16.9 million shares purchased at an average price of R11.75

Earnings per share (EPS), headline earnings per share (HEPS) and normalised earnings per share (NEPS)

The Group's overall earnings have been impacted by:

- the R5.3 billion once-off gain recognised in FY2025 following the completion of the Life Molecular Imaging (LMI) disposal, set off by the R2.9 billion fair value loss recognised on the Piramal liability (original owners of LMI);
- impairments to the value of R107 million recognised mainly related to non-acute businesses.

Total EPS (from continuing and discontinued operations) decreased to 91.1 cents (2025: 263.0 cents) while total HEPS increased to 98.4 cents (2025: negative 112.1 cents).

Prior period pro forma information is provided to exclude the fair value adjustment to the LMI-associated liability. NEPS, which excludes non-trading related items, better reflects the performance of our underlying business and increased by 9.5%.

Earnings per share (cents)	FY2026 Audited	FY2025 Audited	Pro forma adjustments FY2025	Pro forma FY2025 Audited	% change FY2026 vs FY2025	% change FY2026 vs pro forma FY2025
From continuing operations						
NEPS	109.8	100.3	-	100.3	9.5%	9.5%
EPS	96.6	(106.9)	201.0	94.1	>100%	2.7%
HEPS	103.9	(93.9)	201.0	107.1	>100%	(3.0%)
From continuing and discontinued operations						
EPS	91.1	263.0	-	263.0	(65.4%)	(65.4%)
HEPS	98.4	(112.1)	201.0	88.9	>100%	10.7%

Financial position and liquidity

The Group is in a strong financial position as at 30 September 2026, with net debt to normalised EBITDA (as per bank covenant definitions) of 1.06 times (2025: 0.01 times), well within our covenant of 3.5 times.

Cash generated from continuing operations was R3.8 billion and represented 91.8% of normalised EBITDA. The available undrawn bank facilities as at 30 September 2026 amount to R1.7 billion.

Cash dividend

Final dividend

The Board approved a final gross cash dividend of 40.0 cents per ordinary share. The dividend has been declared from income reserves and is subject to South African dividend withholding tax of 20%, which will be applicable to all shareholders not exempt therefrom, after deduction of which the net cash dividend is 32.0 cents per share.

The Company's total number of issued ordinary shares is 1 443 836 000 as at 26 November 2026.

The Company's income tax reference number is 9387/307/15/1.

In compliance with the requirements of the JSE, the following salient dates are applicable:

Last date to trade cum dividend	Monday, 14 December 2026
Trading ex-dividend commences	Tuesday, 15 December 2026
Record date	Friday, 18 December 2026
Payment date	Monday, 21 December 2026

Share certificates may not be dematerialised or rematerialised between Tuesday, 15 December 2026 and Friday, 18 December 2026, both days inclusive.

The Board will approve additional distributions or return capital to shareholders as and when the opportunity arises.

2027 Outlook

Grow

For the 12 months to 30 September 2027 (FY2027), the Group's growth strategy remains focused on expanding its underlying asset base in selected strategic locations. During FY2027, the Group will expand by 158 acute hospital beds, including the opening of the 140-bed Life Paarl Valley Hospital in Q4-FY2027, 40 acute rehabilitation beds and 34 renal stations. The two cyclotrons will start commercial production after completing the regulatory approval process.

Drive

The Group expects paid patient day (PPD) growth to be c. 1.0% resulting in occupancies of c. 69%. Revenue growth for FY2027 is expected to be c. 5%.

Optimise

As part of the Group's cost optimisation programme, the Group remains on track to deliver the R400 million in savings over three years, with a continued focus on improving the EBITDA margin. The asset optimisation programme is expected to be implemented through defined pathways over the next two to three years. A progress update will be provided at the H1-FY2027 results.

Capex for FY2027 is expected to be c.R1.9 billion.

Audit opinion

The Group has issued its audited annual financial statements for the year ended 30 September 2026. Deloitte & Touche, the Group's independent auditor, has audited the consolidated and separate annual financial statements and has expressed an unmodified audit opinion thereon. Deloitte & Touche has also issued a separate assurance report under ISAE3420 on the pro forma information provided.

Thanks

The Company's ability to effectively respond to operational challenges while continuing to provide quality care to its patients is largely due to the resilience, dedication and unwavering support of its employees, specialists and other healthcare professionals.
Life Healthcare would like to thank them for their tireless work and for the care they deliver.

Results announcement

This results announcement is a summary of the information contained in the detailed audited consolidated annual financial statements published on 26 November 2026 and does not contain full or complete details.

The results and the detailed audited consolidated annual financial statements, approved on 25 November 2026, are available on Life Healthcare's website (https://www.lifehealthcare.co.za/investor-relations/results-and-reports/) and through the JSE cloudlink at https://senspdf.jse.co.za/documents/2026/JSE/ISSE/LHC/Final26.pdf

Any investment decisions by shareholders, noteholders and/or investors should be based on consideration of the audited annual financial statements as a whole and shareholders, noteholders and/or investors are encouraged to review the audited annual financial statements, which is available for viewing on the links as set out above.

This results announcement has been prepared in compliance with the JSE Listings Requirements, is the responsibility of Life Healthcare's board of directors, and has not been reviewed nor audited by the Group's auditors.

Executive directors: PG Wharton-Hood (Chief Executive), PP van der Westhuizen (Chief Financial Officer)

Non-executive directors: Dr VL Litlhakanyane (Chairman), Dr MF Abdullah, Prof RA Campbell, CM Henry, TP Moeketsi, AM Mothupi Palmstierna, Adv M Sello, and F Tonelli

Company Secretary: J Ranchhod

Registered Office: Oxford Parks, 203 Oxford Road (cnr Eastwood and Oxford Roads), Dunkeld, 2196

Equity Sponsor: Rand Merchant Bank, a division of FirstRand Bank Limited

Debt Sponsor: Questco Corporate Advisory

Note regarding forward-looking statements: Any forward-looking statements or projections made by the Company, including those made in this announcement, are subject to risk and uncertainties that may cause actual results to differ materially from those projected, are the responsibility of the directors and have not been reviewed or reported on by the Group's external auditors.

Date: 26 November 2026